Copeptin has been reported to be an excellent tool for AMI rapid rule-out when combined with cTn evaluation in patients with potential AMI, as well as for risk stratification and outcome prediction in patients with AMI, HF, and stroke. This evidence concerns the gene AVP and hydrops fetalis.